1. Dyer, O. Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show. BMJ 375, n3104 (2021).
2. Cameroni, E., et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv (2021).
4. Liu L., et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 23 December 2021(2021).
5. Collie, S., Champion, J., Moultrie, H., Bekker, L.G. & Gray, G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med (2021).
6. Goga, A., et al. Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COV2.S vaccine trial, South Africa. MedRxiv (2021).
7. Neil Ferguson, A.G., Wes Hinsley and Erik Volz on behalf of the Imperial College COVID-19 response team. Report 50: Hospitalisation risk for Omicron cases in England. (2021).
8. Wolter N., et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa. bioRxiv (2021).
9. Braun, J., et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270-274 (2020).
10. Grifoni, A., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489-1501 e1415 (2020).
11. Kalimuddin, S., et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med (N Y) 2, 682-688 e684 (2021).
12. Le Bert, N., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457-462 (2020).
13. Oberhardt, V., et al. Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature 597, 268-273 (2021).
14. Peng, Y., et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 21, 1336-1345 (2020).
15. Sekine, T., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell 183, 158-168 e114 (2020).
16. Israelow, B., et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci Immunol 6, eabl4509 (2021).
17. McMahan, K., et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630-634 (2021).
18. Rydyznski Moderbacher, C., et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 183, 996-1012 e1019 (2020).
19. Tan, A.T., et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep 34, 108728 (2021).
20. Tarke, A., et al. Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep Med 2, 100355 (2021).
21. Meng B., et al., SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv (2021).
22. Niessl, J., et al. Identification of resident memory CD8(+) T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. Sci Immunol 6, eabk0894 (2021).
23. Bergman, P., et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine 74, 103705 (2021).